Dimerix (ASX:DXB) recruited the first paediatric patient for the phase-three clinical trial for DMX-200, the company's drug candidate for kidney disease, according to a Thursday filing with the Australian bourse.
The biopharmaceutical company is assessing the efficacy and safety of DMX-200 in patients with focal and segmental glomerulosclerosis (FSGS), a rare disease that attacks the kidney's filtering units, per the filing.
A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK, and the US will recruit patients into the clinical trial.
The biopharmaceutical company expects the blinded interim analysis in August.
Dimerix's shares were up 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。